Talya L Miller1, Julia Schuchard2, Adam C Carle3, Christopher B Forrest2, Michael D Kappelman4. 1. Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC. Electronic address: Talya.Lepow.Miller@gmail.com. 2. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA. 3. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH; Department of Psychology, University of Cincinnati College of Arts and Sciences, Cincinnati, OH. 4. Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC.
Abstract
OBJECTIVES: To evaluate whether Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric patient-reported outcome (PRO) measures can serve as valid endpoints in a clinical trial of a chronic pediatric illness. STUDY DESIGN: We evaluated the responsiveness of PROMIS pediatric measures collected through the Clinical Outcomes of Methotrexate Binary Therapy in Practice (COMBINE) trial, a multicenter, randomized, double-blind, placebo-controlled, pragmatic clinical trial in pediatric patients with Crohn's disease (CD). We examined the relationships between changes in PROMIS pediatric measures and changes in disease activity by evaluating PRO score changes among patients who did and patients who did not experience improvement in disease activity. RESULTS: Participants included 266 children and adolescents with CD from a total of 35 institutions. Over the course of follow-up, participants showed improvement in most PRO domains, with the largest effect sizes observed for the clinically improved group. Patients who maintained steroid-free remission showed significantly lower PRO scores for the Pain Interference, Fatigue, and inflammatory bowel disease (IBD) Symptoms domains and higher scores for the Positive Affect domain. CONCLUSIONS: This study demonstrates the responsiveness of the PROMIS pediatric measures of Fatigue and Pain Interference as study endpoints in a large, multicenter pragmatic trial in pediatric CD, extending a growing body of research supporting the use of PROMIS pediatric measures as reliable PRO endpoints for clinical trials.
OBJECTIVES: To evaluate whether Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric patient-reported outcome (PRO) measures can serve as valid endpoints in a clinical trial of a chronic pediatric illness. STUDY DESIGN: We evaluated the responsiveness of PROMIS pediatric measures collected through the Clinical Outcomes of Methotrexate Binary Therapy in Practice (COMBINE) trial, a multicenter, randomized, double-blind, placebo-controlled, pragmatic clinical trial in pediatric patients with Crohn's disease (CD). We examined the relationships between changes in PROMIS pediatric measures and changes in disease activity by evaluating PRO score changes among patients who did and patients who did not experience improvement in disease activity. RESULTS: Participants included 266 children and adolescents with CD from a total of 35 institutions. Over the course of follow-up, participants showed improvement in most PRO domains, with the largest effect sizes observed for the clinically improved group. Patients who maintained steroid-free remission showed significantly lower PRO scores for the Pain Interference, Fatigue, and inflammatory bowel disease (IBD) Symptoms domains and higher scores for the Positive Affect domain. CONCLUSIONS: This study demonstrates the responsiveness of the PROMIS pediatric measures of Fatigue and Pain Interference as study endpoints in a large, multicenter pragmatic trial in pediatric CD, extending a growing body of research supporting the use of PROMIS pediatric measures as reliable PRO endpoints for clinical trials.
Authors: Kathleen W Wyrwich; Monika Bullinger; Neil Aaronson; Ron D Hays; Donald L Patrick; Tara Symonds Journal: Qual Life Res Date: 2005-03 Impact factor: 4.147
Authors: James W Varni; Brian D Stucky; David Thissen; Esi Morgan Dewitt; Debra E Irwin; Jin-Shei Lai; Karin Yeatts; Darren A Dewalt Journal: J Pain Date: 2010-06-02 Impact factor: 5.820
Authors: Christopher B Forrest; Janine Devine; Katherine B Bevans; Brandon D Becker; Adam C Carle; Rachel E Teneralli; JeanHee Moon; Carole A Tucker; Ulrike Ravens-Sieberer Journal: Qual Life Res Date: 2017-08-21 Impact factor: 4.147
Authors: Michael D Kappelman; Wallace V Crandall; Richard B Colletti; Anthony Goudie; Ian H Leibowitz; Lynn Duffy; David E Milov; Sandra C Kim; Bess T Schoen; Ashish S Patel; John Grunow; Evette Larry; Gerry Fairbrother; Peter Margolis Journal: Inflamm Bowel Dis Date: 2010-09-01 Impact factor: 5.325
Authors: Carlton Dampier; Vaughn Barry; Heather E Gross; Yang Lui; Courtney D Thornburg; Darren A DeWalt; Bryce B Reeve Journal: Pediatr Blood Cancer Date: 2016-02-19 Impact factor: 3.167
Authors: Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: Christopher B Forrest; Kathryn D Forrest; Jennifer L Clegg; Anna de la Motte; Sandra Amaral; Andrew B Grossman; Susan L Furth Journal: J Patient Rep Outcomes Date: 2020-02-12
Authors: Erica J Brenner; Millie D Long; Courtney M Mann; Wenli Chen; Camila Reyes; Li Lin; Bryce B Reeve; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: Christopher B Forrest; Julia Schuchard; Cortney Bruno; Sandra Amaral; Elizabeth D Cox; Kathryn E Flynn; Pamela S Hinds; I-Chan Huang; Michael D Kappelman; Jerry A Krishnan; Rajesh B Kumar; Jin-Shei Lai; Amy S Paller; Wanda Phipatanakul; Laura E Schanberg; Kaharu Sumino; Elissa R Weitzman; Bryce B Reeve Journal: J Pediatr Date: 2022-03-02 Impact factor: 6.314